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visit combined with extended treatment (starting 0–30 days after outpatient visit) 
with ≥ 1 of the following: a further course of intravenous corticosteroids > 7 days 
after the first course; a course of oral corticosteroids > 7 days after the intravenous 
course; intravenous immunoglobulins or plasma exchange. Algorithms for identify-
ing atypical relapses were also developed. ConClusions: General and outpatient 
ARRs are consistent between the two distinct claims databases and are similar to 
those reported in the literature. Differences in inpatient ARRs may indicate differ-
ences between clinical practices in the two systems. Further investigation in the 
real-world setting is required.
PRM44
CoMPaRison of Methods to identify stage iiiB oR iV MetastatiC Lung 
CanCeR Patients fRoM eLeCtRoniC MediCaL ReCoRds
Stafkey-Mailey D., Landsman-Blumberg P., Farrelly E., Eaddy M.
Xcenda, Palm Harbor, FL, USA
objeCtives: Increased use of electronic medical records (EMR) has necessitated 
efficient ways to identify patients with certain clinical characteristics. This study 
compared use of standard fields and standard language recognition of progress 
notes to identify patients with metastatic lung cancer within an oncology-specific 
EMR. Methods: Lung cancer patients (ICD-9-CM: 162.2 - 162.9) with second line 
erlotinib treatment were identified from a proprietary EMR. Method 1 identified 
metastatic disease using standard data fields for diagnoses (196.x – 198.x) and/
or stage (3B/IIIB or 4/IV); Method 2 utilized keyword searches for indications of 
metastases or stage within progress notes. Chart reviews were used to confirm 
advanced disease. Positive and negative predictive values (PPV and NPV) were then 
compared across methods. Results: A total of 740 patients were identified with 
suspected metastatic disease; 60.1% (n= 448) using Method 1. Of the remaining 292 
patients, 282 (96.5%) were identified by metastases and 117 (40.1%) by stage key-
words (Method 2). Overall, 671 (86.6%) were confirmed “metastatic” with chart review 
and 5 patients excluded for evidence of other cancers. Overall, PPV was 100% and 
NPV 6.3%. Of those identified as metastatic using the standard fields, the PPV for 
metastases and stage were 65.5% and 66.3% respectively and 99.3% combined. The 
PPV and NPV among the 287 patients identified only by keyword searches, was 
98.2% and 8.7% respectively for metastases and 49.3% and 89.9% respectively for 
stage. ConClusions: Utilization of standard EMR fields for diagnosis and disease 
stage, when used together, resulted in identification of large numbers of confirmed 
metastatic lung cancer patients. However, for those patients requiring text searches 
for metastases and stage, neither separately nor in combination, could adequately 
identify metastatic disease patients. Further standardization of EMRs and consistent 
entry within oncology practices could reduce the need for labor-intensive, costly 
human chart review in real-world oncology research.
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objeCtives: Observational data derived from clinical practice is becoming increas-
ingly important to answer questions that cannot be addressed by RCTs. Although 
there are a number of administrative databases in Canada, access to more com-
prehensive, longitudinal clinical data such as smoking status, body weight and 
laboratory values in the primary care setting is limited. The objective of this study 
was to evaluate a Primary Care EMR (Electronic Medical Record) system to deter-
mine its feasibility for use in observational studies. Methods: We analyzed de-
identified patient data from primary Health Care Professionals (HCPs) including 
General Practitioners from 2009-2011. Comprehensiveness and completeness of 
each variable by visit were evaluated. First steps were taken to understand how the 
patient population compares to data from published sources. Results: There were 
3,019,954 patient visits observed by 255,274 active patients (≥ 1 visit). The patient vis-
its were entered by 497 HCPs (152 physicians). Data are available for demographics, 
vitals, smoking status, laboratory values, prescriptions, medical history, diagnosis 
(ICD-9), short term absences and referrals. Completeness of each variable by visit 
ranged from 26% for pulse to 100% for age, sex, lab results and referrals. Initial 
assessment revealed that 85.6% of written prescriptions and 88% of diagnoses were 
recorded using structured fields. The median age of patients in the EMR was 37.2 
years compared to 39.9 years reported by Statistics Canada (July 2011). Younger 
age groups were overrepresented, with the largest difference found in those 20-29 
years; no difference was observed for sex. ConClusions: The status of electronic 
primary care health records in Canada is still in its infancy. The research suggests 
this is a valuable new addition to support observational studies in Canada. Disease 
specific validation studies will be required prior to further analysis. Further research 
is being undertaken to review quality measures.
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objeCtives: The Brazilian Network for Health Technology Assessment (REBRATS) 
is composed of universities, hospitals and managing institutions who have among 
their goals the objective to elaborate and disseminate HTA information. The net-
work’s website and database are found at the http://www.saude.gov.br/rebrats and 
are tools to disseminate the policies and methodological guidelines of the network’s 
institutional organization and the studies produced by its members. To evaluate 
the degree of the network’s dissemination on national and international levels by 
analyzing the level of access and the rate of return from site users. Methods: To 
analyze the number of visits to the REBRATS site registered through the Google 
Analytics monitoring and data extraction tool, with the intention of identifying 
warrants further investigation. Robust analyses are planned to comprehensively 
describe the clinical and economic burden of TSC in the UK.
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exPLoRing the identifiCation of MuLtiPLe sCLeRosis inCident CohoRts 
in CLaiMs dataBases: MethodoLogy and ChaLLenges
Capkun-Niggli G.1, Lahoz R.1, Nordstrom B.2, Fraeman K.2, Chen W.3, Simeone J.C.2, Dickinson S.1
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objeCtives: To explore whether multiple sclerosis (MS) incident cohorts can be 
identified in claims databases. Methods: We used several approaches to try 
and identify MS incident cohorts in the US Department of Defense (DOD) and 
MarketScan® databases, based on diagnostic and treatment history. Patients were 
first identified with 1 year of no MS claims or treatment before their first MS 
claim. Sensitivity analyses identified patients with 1–4 years of no MS claims or 
treatment before their first MS claim. Results: In patients with a 1-year baseline 
history with no MS claims or treatment, age and baseline characteristics were 
similar to all MS patients. The mean age at index date (second MS claim) was ~50 
years, in contrast with previous research reporting a mean age at diagnosis of 
25–40 years. Patients aged ≤ 65 years with ≥ 1 MS claim and 4 years of continuous 
baseline enrolment were identified in the DOD (n= 16 444) and MarketScan® (n= 16 
352) databases. With increasing years of baseline history, more patients showed 
evidence of pre-existing MS; the percentage of total patients with no MS claim or 
treatment before the first MS claim decreased from 53.3% (1 year history) to 42.2% 
(4 years history) in the DOD database, and from 23.5% to 15.5% in MarketScan®. 
Despite the decrease in patient numbers, the mean age at index date remained 
high (44–49 years). ConClusions: Results indicate that > 4 years of patient his-
tory is needed to define an incident MS cohort in claims databases. However, the 
4-year claim and treatment-free cohort may be useful for studying treatment 
patterns and their impact on outcomes in recently treatment-naïve MS patients. 
There are substantial challenges in retrospectively identifying incident cohorts 
of MS patients using claims databases and a need for additional, large, real-world 
data sources to study newly diagnosed MS patients.
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sCReening ChaRaCteRistiCs and diaBetes BioMaRkeRs in fRenCh and 
uk Patient-LeVeL dataBases
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objeCtives: Describe the patient characteristics and diabetes markers of type 
2 diabetes (T2D) patients in the newly launched IMS LifeLink Diabetes Cohort in 
France. Monitor the data quality through comparison of measures with a French 
national survey of diabetes patients (ENTRED), the UK National Diabetes Audit (NDA) 
where possible, and the “gold standard” UK Clinical Practice Research Datalink 
(CPRD). Methods: The IMS Diabetes cohort in France supplements patient-level 
data from general practitioners with additional patient data via pop-up technol-
ogy within electronic medical records to facilitate robust epidemiological studies. 
This study compares the T2D patients in the Diabetes Cohort with similar popula-
tions in terms of gender, age, disease duration, and proportion of patients meet-
ing key disease-specific targets (data presented as summary statistics). Results: 
Patient characteristics and diabetes markers were analyzed for T2D patients in the 
Diabetes Cohort (n= 5,142), ENTRED (n= 3,894), UK NDA (n= 1,909,494), and UK CPRD 
(n= 268,618). The mean (SD) age in years was 66 (12.58) in the Diabetes Cohort, 66 
in ENTRED, and 61 (15.35) in CPRD. The mean (SD) time since T2D diagnosis was 
8 (7.7), 11, and 7.7 (6.2) years in the Diabetes Cohort, ENTRED, and CPRD, respec-
tively. Mean (SD) BMI was 30.5 (5.76) in the Diabetes Cohort, 29.5 in ENTRED, and 
30.8 (6.51) in CPRD. HbA1c target level of ≤ 6.5% was met by 32.5%, 34%, 23.5%, 
and 26% of the patients in the Diabetes Cohort, ENTRED, CPRD, and NDA, respec-
tively. ConClusions: Health care systems and data collection methods vary across 
EU countries in general. Data monitoring helps assess data quality and robust-
ness. Based on comparison of patient characteristics and diabetes markers, the 
IMS Diabetes Cohort population does not appear to differ from the ENTRED popula-
tion. Although some differences between the Diabetes Cohort and CPRD data were 
noted, this unique French Diabetes Cohort appears appropriate for epidemiological 
research.
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MediCaL and PhaRMaCy CLaiMs-Based aLgoRithMs foR identifying 
ReLaPses in Patients with MuLtiPLe sCLeRosis
Capkun-Niggli G.1, Lahoz R.1, Verdun E.1, Dickinson S.1, Lowy A.1, Nordstrom B.2, Dahlke F.1
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objeCtives: To develop appropriate algorithms for identifying and classifying 
relapses among patients with multiple sclerosis in claims databases. Methods: 
Algorithms for detecting relapses in claims databases were identified by literature 
searches and refined by neurologists and database experts to identify relapses in 
inpatient and outpatient settings. Definitions were used in the US Department of 
Defense (DOD) and MarketScan® databases to determine annualized relapse rates 
(ARR) occurring after index date (date of second MS medical claim separated by ≥ 30 
days, following ≥ 12 months of continuous enrollment) during the 12-month and all 
available follow-up time. Results: A relapse was defined as an inpatient visit with 
a primary ICD-9-CM diagnosis code 340.xx or both an outpatient visit with any 340.
xx diagnosis code and oral or intravenous corticosteroid use ≤ 7 days of the outpa-
tient visit. ARR estimates in the DOD (N= 15,447) and MarketScan® (N= 35,134) data-
bases were 0.25–0.30 and 0.20–0.27, respectively. For inpatient relapses, estimates 
were 0.04–0.06 in the DOD database and 0.02–0.03 in the MarketScan® database. The 
corresponding estimates for outpatient relapses were 0.20–0.23 and 0.18–0.24. Severe 
relapses required an inpatient visit plus additional evidence of brain or spinal mag-
netic resonance imaging ≤ 7 days before or during hospitalization, or an outpatient 
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include = > 1 cohorts, retrospective or prospective data collection, disease or treat-
ment-based inclusion criteria, various outcomes (safety, prescription pattern or 
off-label use, comparative effectiveness, quality of life or other patient-reported 
outcomes[PRO], health economics, or other objectives), site/investigator selection 
(in-house, commercial, professional organization, or government databases), and 
country-specific requirements. Methods: Studies that used integrated and non-
integrated DM systems were evaluated to identify criteria for use and associated 
protocol template language (PTL), including required, preferred, or optional text 
based on various study designs and objectives. Results: Multiple DM systems were 
evaluated and algorithms created with use criteria. For integrated DM systems that 
combined data capture and trial management, simplified PTL was identified. DM 
PTL was adjusted to include paper or electronic data capture (EDC) methods, paper/
electronic-based PROs, paper/electronic case report forms (CRFs), data (eg. subject/
physician entered, site or aggregate, medical or laboratory records) and appropriate 
subject data protection. For non-integrated systems that required separate DM and 
trial management, additional PTL was identified for these complex DM systems. The 
templates denoted minimum required language and suggested extended language 
for more elaborate designs. To support the numerous NIS study design types, we 
included decision trees to account for various study goals, associated outcomes, 
and data collection requirement. Our data collection decision tree summarized the 
variety of potential study designs with frequently used study goals/outcomes and 
associated data collection techniques. ConClusions: Integrated DM systems pro-
vided the most flexibility and simplicity of protocol template language. All template 
language was created as adjustable to meet the typical study designs encountered 
in PASS studies. This additional information was to support the protocol devel-
opment team in creating the final protocol in a timely manner and in reviewing 
client-provided templates.
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Link RaRe disease Patients: Case study of MyeLofiBRosis Patients in 
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Cohen P.6
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objeCtives: Conducting real world evidence (RWE) research on patients with rare 
diseases is particularly challenging when using only one type of data (e.g. insur-
ance claims). Myelofibrosis (MF) is a rare, hematological cancer with global annual 
incidence rate of < 1 - 2.4 cases per 100,000 patients. MF is characterized by the 
reduced ability of bone marrow to synthesize blood cells which can result in anemia, 
thrombocytopenia, and higher risk of infection. Absent adequate, recent data on MF 
patients, a practice-based network (PBN) data platform was developed to facilitate 
RWE research on MF patients. Methods: MF patients observed in IMS Health data-
bases between November 2010 to October 2012 were identified. Academic centers of 
excellence and large community oncology practices treating MF patients were then 
identified to link additional patients into the platform using a HIPAA-compliant 
patient de-identification algorithm. Patient demographics and attributes of dis-
pensed prescriptions, private practitioner visits, and electronic medical record data 
including laboratory information were collected across patients from January 2000 
to March 2013. Descriptive analyses of demographic and clinical characteristics were 
conducted to assess the generalizability of the sample versus literature. Results: 
A total of 6362 U.S. MF patients were identified in the platform. Mean (SD) age was 
67 (12.6) and 45% of patients were female. Mean (SD) Charlson Comorbidity Index 
was 4.36 (2.4). Among the subset of 529 patients with laboratory results, 63% were 
identified as anemic and 34% had platelet counts 50,000 - 100,000 / microL. All U.S. 
geographic regions were represented. ConClusions: Demographic and clinical 
results suggest that this large sample of MF patients is comparable to prior esti-
mates of the broader MF population. This case study of U.S. MF patients suggests it 
is important to look beyond any one data source and to build PBN platforms with 
key clinical domains spanning multiple geographic regions when conducting RWE 
research on patients with rare diseases.
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objeCtives: Observational studies are often planned on an ad hoc basis, with 
the risk that methods are inconsistent and that aims overlap rather than comple-
ment each other. Our objective was to develop a systematic approach for identify-
ing observational data sources for an integrated global programme of real-world 
evidence gathering, to support an important new indication for an antiplatelet 
drug. Methods: Systematic literature and Web searches, supplemented with email 
and telephone contact with data owners, were used to identify and characterize 
registries and health care databases suitable for use in observational studies of 
myocardial infarction and acute coronary syndromes. The ability to identify patients 
across data sources was also assessed. Data were captured and evaluation criteria 
applied, including compatibility with aspects of an ongoing randomized clinical 
trial (patient population, treatments, outcomes, and length of follow-up [≥ 3 years]). 
Selection criteria included accessibility; availability of inpatient, outpatient, cardiac 
event, and drug data; and generalizability. Results: Over 2700 publications were 
screened; we identified 216 registries and 380 databases (primarily of administra-
tive claims and electronic medical records). Of these, 12 registries, and 21 databases 
met the evaluation criteria and were assessed in depth. After application of the 
selection criteria, 5 registries and 12 databases were recommended. Recommended 
data sources ranged in size, each capturing data on between 4000 and 11 million 
the user’s behavior upon navigating the site. Results: Since the site began to get 
monitored on July 1, 2012 and up until June 25, 2013, 19.738 hits were registered, with 
a monthly average of 1.661 hits. More than 65 countries accessed the site, the major-
ity coming from the USA, UK and Portugal. Brazil leads with 93%. The rate of return 
of people who frequently accessed the site was 24,7%. Upon navigating the site, 
more than 45.000 visualizations of the web page were registered. ConClusions: 
This monitoring began in 2012 and therefore no previous years exist to serve as a 
basis for comparison. The results show that a considerable number of users have 
access to the site and consequently know about REBRATS. From the perspective of 
the website, the number of hits is still low, however, considering that the HTA field 
is a recent one in Brazil, its growth has been gradual. On an international level, 
new dissemination strategies are necessary in order to create greater visibility and 
promotion of the network.
PRM47
desCRiPtion of tReatMent Pathways in ChRoniC diseases using LaRge 
geneRaL PRaCtitioneR LongitudinaL data: the exaMPLe of PhaRMaCo-
theRaPy in PaRkinson’s disease in the united kingdoM
Guelfucci F.1, Neine M.2, Bineau S.3, Milea D.3, Aballea S.2
1EPHE Sorbonne, Paris, France, 2Creativ-Ceutical, Paris, France, 3Lundbeck S.A.S., Issy-Les-
Moulineaux, France
objeCtives: Identifying treatment pathways based on administrative data or elec-
tronic medical records is generally a complex task, as many incidental events may 
hide the key trends. The purpose of this study was to propose a transparent method-
ology for defining treatment pathways using a large longitudinal real life database. 
The application of two alternative algorithms with different variants in Parkinson’s 
disease (PD) was described. Methods: In the first method, a new treatment line 
was assumed to start when a pre-specified number of consecutive prescriptions of 
drugs from the same PD drug class or combination of classes (rasagiline, selegiline, 
dopa agonists, COMT inhibitors, levodopa and derivatives) occurred. In the second 
method, start and end dates of continuous treatment periods (i.e. without gaps 
higher than six months between prescriptions) were determined for each drug class 
independently of each other. Combinations were assumed to be used when differ-
ent treatment periods overlapped. Algorithms were tested using medical records 
of patients with Parkinson’s disease (PD) extracted from the UK Clinical Practice 
Research Datalink (CPRD). The outputs of the different algorithms were described 
in details for ten patients, randomly selected. The sensitivity of the algorithms to 
changes in assumptions was tested. Results: The first algorithm did not systemat-
ically capture the addition of a new drug to the current treatment as combined drugs 
were not necessarily prescribed or renewed during the same consultations. However, 
the second method well captured the treatment lines observed but sometimes cre-
ated undue treatment lines from isolated prescriptions. This issue was overcome 
by deleting short lines lasting less than three months. ConClusions: The second 
algorithm developed in this study provided an accurate description of the treatment 
strategies developed by prescribers in Parkinson’s disease in the UK using a limited 
number of assumptions and may be useful for other chronic diseases.
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identifiCation and QuaLitatiVe assessMent of ReaL woRLd data 
souRCes: exaMPLe of LyMPhoMa and MuLtiPLe MyeLoMa in euRoPe
Noibi S.O.1, Bertwistle D.1, MacDougall F.1, Berger K.1, Mehta J.2, Trask P.C.2
1IMS Health, London, UK, 2Sanofi, Cambridge, MA, USA
objeCtives: To identify and assess real world data sources for observational 
research on lymphoma and multiple myeloma (myeloma) in Europe. Methods: 
Structured (EMBASE and MedLine) and grey literature searches were conducted 
to identify relevant European data sources. Identified data sources were screened 
based on the following criteria: inclusion of patient-level data and patients with 
NHL, HL, or MM diagnoses, possession of data dictionaries, and ongoing data accrual. 
Where regional registries were proven to feed data into national registries, only 
the national data source was retained for evaluation. Data sources passing initial 
screening were subjected to further evaluation based on publicly reported infor-
mation, questionnaires and / or interviews with data source owners, and informed 
by lymphoma and myeloma treatment pathway analysis. Results: One hundred 
eighty-six data sources from 21 countries were identified; of which cancer regis-
tries (R) accounted for 65%. The remaining 35% non-registry (NR) sources included 
biobanks, clinical audits, data linkage initiatives, drug databases and electronic 
medical records. Screening removed 101 sources. Of the 85 sources retained after 
screening, roughly half (52%) were NR sources and a majority (74%) were from six 
countries: France, Germany, Spain, Sweden, The Netherlands, and The UK. NR data 
sources generally collected more data attributes than R data sources. These data 
attributes included symptoms (collected by 52% NR, and 21% R data sources), treat-
ment regimens (81% NR, 40% R), and resource use (49% NR, 8% R). ConClusions: 
Compared with disease registries, non-registry data sources in Europe typically have 
more diverse data attributes and are therefore potentially better for lymphoma and 
myeloma research. This result may guide the selection of data sources for observa-
tional research. As scrutiny of real-world outcomes for reimbursement of oncology 
drugs increases, much work remains to be done to increase the visibility and utility 
of data sources for health care payers and providers.
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(PtL) foR data CoLLeCtion and data ManageMent (dM) in Post-
authoRization safety studies (Pass)
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Gulyas S.1, Clark S.1
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objeCtives: To address non-interventional study (NIS) protocol DM and data 
collection requirements in PASS observational study designs. These studies may 
